NCT02809963View on ClinicalTrials.gov

Mineralocorticoid Receptor Antagonists in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Diabetes Type 2
Interventions
DRUG

Eplerenone

50 mg tablets, oral use.

DRUG

Placebo

50 mg tablets, oral use

Trial Locations (1)

2730

Herlev and Gentofte Hospital, Department of Endocrinology and Metabolism, Department of internal medicine,, Herlev

All Listed Sponsors
lead

Herlev Hospital

OTHER

NCT02809963 - Mineralocorticoid Receptor Antagonists in Type 2 Diabetes | Biotech Hunter | Biotech Hunter